Coronary heart disease (CHD) is the commonest cause of morbidity and mortality worldwide. Our country, as a developing one is facing also with many, “new fashioned” diseases, which are becoming epidemic in developed world, such as: obesity, diabetes mellitus, hypercholesterolemia, stress and unhealthy diet.
Objective
The aim of this study is To present food patterns in schoolchildren in our region and To stress the role of healthy nutrition in the prevention of CHD.
Methods
Two hundred schoolchildren, aged from 7–15 years, examined at University Children’s Hospital, are included in this study. They are selected at random and mostly suffer from respiratory infections, throat infections, rheumatic fever, etc. Except history, physical examination, laboratory and anthropometric measures, an questionnaire regarding to food habits was filled by all patients.
Results
Of 200 examined children, there were 150 (75.0%)with normal weight (< 97 percentile), 36 (18.0%) underweight (< 3 percentile) and 14 (7.0%) overweight ore obese (>97 percentile). There were 10 (5.0%) children with dislypidaemia and 6 (3.0%) with hypertension. The questionnaires analysis revealed many unhealthy habits: 75.0% prefer processed and fast food, 85.0% sweetened fruit drinks and soda. On the other hand, the consumption of healthy food, such as: milk, honey, fruits, whole grains, vegetables, functional foods, fish etc is very low.
Conclusion
This paper underlines the link between food and health, especially in children; they, as a very vulnerable segment of population are often “victims” of food industry which offer them: high content of salt, sugar, trans fat.
Several therapeutic methods are used to cure acute lymphoblastic leukemia (ALL). Relapsed/refractory B-cell <em>ALL</em> (R/R B-ALL) remains the primary cause of death worldwide due to the limitation of cure. Blinatumomab is a bispecific T-cell engaging antibody used to treat R/R B-ALL. The use of blinatumomab for treating R/R B-ALL has shown to be very efficient, especially as a bridge tool to hematopoietic stem cell transplantation (HSCT). The response to blinatumomab treatment ranged from 69% after two cycles in phase II clinical trials. Blinatumomab has shown great anti-leukemia activity as a single agent in children with R/R B-ALL. Here, we will review the data from several research groups that show pharmacological and clinical data on blinatumomab for pediatric and adult B-ALL, both as an immunotherapeutic and in combination.